In this study, we systematically analyzed the anti-leukemia activity of BH3-mimetics selectively targeting BCL-2 (venetoclax), BCL-XL (A-1331852) or MCL-1 (S63845) in BCP-ALL. Here, BCL2 is linked to leukemia.